Skip to main content
SpringerLink
Log in

Antiparasitic Agents for Pediatric Infections, and Hearing Loss

  • Chapter
  • First Online:
Hearing Loss in Congenital, Neonatal and Childhood Infections

Part of the book series: Comprehensive ENT ((CENT))

  • 231 Accesses

Abstract

Parasitic diseases are responsible for significant morbidity, mortality, disability, and healthcare costs worldwide [1]. Most parasitic diseases affect tropical and subtropical low- and middle-income countries and impoverished people. Parasites live on or inside the host and obtain their nutrients from the host. These organisms can be classified as protozoa, helminths, and ectoparasites [2]. Most parasitic organisms are responsible for the neglected diseases categorized, and more research is needed for their treatment and eradication. Most currently used antiparasitic drugs were developed decades ago, and pharmaceutical companies have not shown much interest in developing new drugs. Many organizations have started to make great efforts to recover patients with these diseases and develop new drugs in recent years.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Al Jalali V, Zeitlinger M. Systemic and target-site pharmacokinetics of antiparasitic agents. Clin Pharmacokinet. 2020;59:827–47.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Centers for Disease Control and Prevention. Parasites. https://www.cdc.gov/parasites/about. Accessed 26 Oct 2022.

  3. Campbell S, Soman-Faulkner K. Antiparasitic drugs. In: StatPearls [internet]. Treasure Island, FL: StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK544251/. Accessed 26 Oct 2022.

    Google Scholar 

  4. Keiser J, Ingram K, Utzinger J. Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy, and implications for control. Parasitology. 2011;138:1620–32.

    Article  CAS  PubMed  Google Scholar 

  5. Dziduch K, Greniuk D, Wujec M. The current directions of searching for antiparasitic drugs. Molecules. 2022;27(5):1534.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rizk HG, Lee JA, Liu YF, Endriukaitis L, Isaac JL, Bullington WM. Drug-induced ototoxicity: a comprehensive review and reference guide. Pharmacotherapy. 2020;40:1265–75.

    Article  CAS  PubMed  Google Scholar 

  7. Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP. Ototoxicity: a challenge in diagnosis and treatment. J Audiol Otol. 2018;22:59–68.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Cianfrone G, Pentangelo D, Cianfrone F, et al. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur Rev Med Pharmacol Sci. 2011;15:601–36.

    CAS  PubMed  Google Scholar 

  9. Arslan E, Orzan E, Santarelli R. Global problem of drug-induced hearing loss. Ann N Y Acad Sci. 1999;884:1–4.

    Article  CAS  PubMed  Google Scholar 

  10. Drug-induced hearing loss. Prescrire Int. 2014;23:290–4.

    Google Scholar 

  11. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588–96.

    Article  PubMed  Google Scholar 

  12. Fligor BJ. Pediatric ototoxicity: current trends and management. Semin Hear. 2019;40:154–61.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30:2408–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Garinis AC, Kemph A, Tharpe AM, Weitkamp JH, McEvoy C, Steyger PS. Monitoring neonates for ototoxicity. Int J Audiol. 2018;57:54–61.

    Article  Google Scholar 

  15. Handelsman JA, Nasr SZ, Pitts C, King WM. Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides. Pediatr Pulmonol. 2017;52:1157–62.

    Article  PubMed  Google Scholar 

  16. Lanvers-Kaminsky C, Zehnhoff-Dinnesen AA, Parfitt R, Ciarimboli G. Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies. Clin Pharmacol Ther. 2017;101:491–500.

    Article  CAS  PubMed  Google Scholar 

  17. Ng TT, Rhee CK, Lee CS, Park YS, Choi DC. Ototoxicity of salicylate, nonsteroidal anti-inflammatory drugs, and quinine. Otolaryngol Clin N Am. 1993;26:791–810.

    Article  Google Scholar 

  18. Bortoli R, Santiago M. Chloroquine ototoxicity. Clin Rheumatol. 2007;26:1809–10.

    Article  PubMed  Google Scholar 

  19. Ryan ET, Gutman JR, Chancey RJ. Antiparasitic agents. In: Long SS, Prober CG, Fischer M, Kimberlin DW, editors. Principles and practice of pediatric infectious diseases. 6th ed. Philadelphia: Elsevier; 2023. p. 1598–617.

    Chapter  Google Scholar 

  20. Weller PF. Anthelminthic therapies. In: Leder K, editor. UpToDate. Waltham, MA: UpToDate; 2022. https://www.uptodate.com/contents/anthelminthic-therapies. Accessed 26 Oct 2022.

    Google Scholar 

  21. Hong ST. Albendazole and praziquantel: review and safety monitoring in Korea. Infect Chemother. 2018;50:1–10. https://doi.org/10.3947/ic.2018.50.1.1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. 2020;178:104787.

    Article  CAS  PubMed  Google Scholar 

  23. Chandler RE. Serious neurological adverse events after ivermectin - do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. 2018;98:382–8.

    Article  CAS  PubMed  Google Scholar 

  24. Little C, Cosetti MK. A narrative review of pharmacologic treatments for COVID-19: safety considerations and ototoxicity. Laryngoscope. 2021;131:1626–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Centers for Disease Control and Prevention. Malaria. https://www.cdc.gov/malaria/about/. Accessed 26 Oct 2022.

  26. Travassos M, Laufer MK. Antimalarial drugs: an overview. In: Daily J, editor. UpToDate. Waltham, MA: UpToDate; 2022. https://www.uptodate.com/contents/antimalarial-drugs-an-overview. Accessed Oct 26, 2022.

    Google Scholar 

  27. Jourde-Chiche N, Mancini J, Dagher N, et al. Antimalarial ototoxicity: an underdiagnosed complication? A study of spontaneous reports to the French pharmacovigilance network. Ann Rheum Dis. 2012;71:1586.

    Article  PubMed  Google Scholar 

  28. Schellack N, Naude A. An overview of pharmacotherapy-induced ototoxicity. S Afr Fam Pract. 2013;55:357–65.

    Article  Google Scholar 

  29. Jozefowicz-Korczynska M, Pajor A, Grzelczyk WL. The ototoxicity of antimalarial drugs—a state of the art review. Front Neurol. 2021;12:661740.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Cabral AML, Rocha MFB, Duarte DSB, et al. Auditory and vestibular changes associated with the use of mefloquine: an integrative review. Audiol Commun Res. 2021;26:e2386.

    Article  Google Scholar 

  31. Lee SJ, Ter Kuile FO, Price RN, Luxemburger C, Nosten F. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: a pooled analysis of 19 850 individual patients. PLoS One. 2017;12:e0168780.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Dayan AD. Neurotoxicity and artemisinin compounds do the observations in animals justify limitation of clinical use? Med Trop. 1998;58:32–7.

    CAS  Google Scholar 

  33. Genovese RF, Newman DB, Li Q, Peggins JO, Brewer TG. Dose-dependent brainstem neuropathology following repeated arteether administration in rats. Brain Res Bull. 1998;45:199–202.

    Article  CAS  PubMed  Google Scholar 

  34. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg. 2004;98:261–7.

    Article  PubMed  Google Scholar 

  35. Carrara VI, Phyo AP, Nwee P, et al. Auditory assessment of patients with acute uncomplicated plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand. Malar J. 2008;7:233.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Dillard LK, Fullerton MA, McMahon MC. Ototoxic hearing loss from antimalarials: a systematic narrative review. Travel Med Infect Dis. 2021;43:102117.

    Article  CAS  PubMed  Google Scholar 

  37. Andersson H, Askling HH, Falck B, Rombo L. Well-tolerated chemoprophylaxis uniformly prevented Swedish soldiers from plasmodium falciparum malaria in Liberia, 2004-2006. Mil Med. 2008;173:1194–8.

    Article  PubMed  Google Scholar 

  38. Della Porta A, Bornstein K, Coye A, Montrief T, Long B, Parris MA. Acute chloroquine and hydroxychloroquine toxicity: a review for emergency clinicians. Am J Emerg Med. 2020;38:2209–17.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Subramaniam V, Vaswani RV. Assessment of short-term chloroquine-induced ototoxicity in malaria patients. Global J Med Res. 2015;15:14–7.

    Google Scholar 

  40. Zhao SZ, Mackenzie IJ. Deafness: malaria as a forgotten cause. Ann Trop Paediatr. 2011;31:1–10.

    Article  PubMed  Google Scholar 

  41. Gurkov R, Eshetu T, Miranda IB, et al. Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J. 2008;7:179.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev. 2021;2:CD013587.

    PubMed  Google Scholar 

  43. De Luca P, Scarpa A, De Bonis E, et al. Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. Am J Otolaryngol. 2021;42:102640.

    Article  PubMed  Google Scholar 

  44. Weller PF. Antiprotozoal therapies. In: Leder K, editor. UpToDate. Waltham, MA: UpToDate; 2022. https://www.uptodate.com/contents/antiprotozoal-therapies. Accessed 26 Oct 2022.

    Google Scholar 

  45. Jafari G, Hosseini SM, Akhondzadeh S. Sudden hearing loss subsequent to diarrhea: what is the missing link? Daru. 2014;22:15.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Bisht M, Bist SS. Ototoxicity: the hidden menace. Indian J Otolaryngol Head Neck Surg. 2011;63:255–9.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Starrs ME, Yenigun OM. Metronidazole, an uncommon cause of dizziness and ataxia in the emergency department: a case report. Clin Pract Cases Emerg Med. 2021;5:239–41.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Iqbal SM, Murthy JG, Banerjee PK, Vishwanathan KA. Metronidazole ototoxicity—report of two cases. J Laryngol Otol. 1999;113:355–7.

    Article  CAS  PubMed  Google Scholar 

  49. Riggs LC, Shofner WP, Shah AR, Young MR, Hain TC, Matz GJ. Ototoxicity resulting from combined administration of metronidazole and gentamicin. Am J Otol. 1999;20:430–4.

    CAS  PubMed  Google Scholar 

  50. Araujo DF, Fernández CG, Asensi-Diez R. Hearing loss associated with paromomycin treatment in a patient with visceral leishmaniasis. Farm Hosp. 2017;41:433–4.

    Google Scholar 

  51. Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169:337–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Valete-Rosalıno CM, Araujo-Melo MH, Bezerra DCO, et al. First report on ototoxicity of meglumine antimoniate. Rev Inst Med Trop Sao Paulo. 2014;56:439–42.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Ordel H, Cailhol J, Matheron S, et al. Atovaquone-proguanil in the treatment of imported uncomplicated plasmodium falciparum malaria: a prospective observational study of 553 cases. Malar J. 2013;12:399.

    Article  Google Scholar 

  54. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis. 2001;33:1015–21.

    Article  CAS  PubMed  Google Scholar 

  55. Zuckerman JM, Qamar F, Bono BR. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin N Am. 2009;23:997–1026.

    Article  Google Scholar 

  56. Etminan M, Westerberg BD, Kozak FK, Guo MY, Carleton BC. Risk of sensorineural hearing loss with macrolide antibiotics: a nested case-control study. Laryngoscope. 2017;127:229–32.

    Article  CAS  PubMed  Google Scholar 

  57. Ress ED, Gross EM. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol. 2000;109:435–7.

    Article  CAS  PubMed  Google Scholar 

  58. Tanaka M, Hasegawa S, Nakao S, et al. Analysis of drug-induced hearing loss by using a spontaneous reporting system database. PLoS ONE. 2019;14:e0217951.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Dismukes WE. Antifungal therapy: lessons learned over the past 27 years. Clin Infect Dis. 2006;42:1289–96.

    Article  CAS  PubMed  Google Scholar 

  60. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016;63:e202–64.

    Article  PubMed  Google Scholar 

  61. Das P, Kandel R, Sikka K, Dey A. Reversible ototoxicity: a rare adverse reaction of liposomal amphotericin-B used for the treatment of antimony-resistant visceral leishmaniasis in an elderly male. Clin Med Insights Case Rep. 2014;7:63–6.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Ramu R, Sharma B, Karunakara D, Paliwal P, Bansal N, Taneja RS. Liposomal amphotericin B-induced reversible ototoxicity in a patient with disseminated histoplasmosis. Indian J Pharmacol. 2021;53:157–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Johnson M. Clindamycin: an overview. In: Hooper DC, editor. UpToDate. Waltham, MA: UpToDate; 2022. https://www.uptodate.com/contents/clindamycin-an-overview. Accessed 26 Oct 2022.

    Google Scholar 

  64. Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. Language of early- and later-identified children with hearing loss. Pediatrics. 1998;102:1161–71.

    Article  CAS  PubMed  Google Scholar 

  65. Downs MP, Yoshinaga-Itano C. The efficacy of early identification and intervention for children with hearing impairment. Pediatr Clin N Am. 1999;46:79–87.

    Article  CAS  Google Scholar 

  66. Smith RJH, Gooi A. Hearing loss in children: etiology. In: Isaacson GC, editor. UpToDate. Waltham, MA: UpToDate; 2022. https://www.uptodate.com/contents/hearing-loss-in-children-etiology. Accessed 26 Oct 2022.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Çukurova University, Adana, Türkiye

    Ümmühan Çay

  2. Division of Pediatric Infectious Diseases, Department of Pediatrics, School of Medicine, Texas Tech University, Lubbock, TX, USA

    Fatma Levent

  3. Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Kocaeli University, Kocaeli, Türkiye

    Emin Sami Arısoy

Authors
  1. Ümmühan Çay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatma Levent
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emin Sami Arısoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ümmühan Çay .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, University of Kocaeli, Medical Faculty, İzmit, Kocaeli, Türkiye

    Ayşe Engin Arısoy

  2. Department of Pediatrics, University of Kocaeli, Medical Faculty, İzmit, Kocaeli, Türkiye

    Emin Sami Arısoy

  3. Department of Otorhinolaryngology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Türkiye

    Nuray Bayar Muluk

  4. Department of Otorhinolaryngology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Türkiye

    Cemal Cingi

  5. Division of Academic General Pediatrics, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

    Armando G. Correa

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Çay, Ü., Levent, F., Arısoy, E.S. (2023). Antiparasitic Agents for Pediatric Infections, and Hearing Loss. In: Arısoy, A.E., Arısoy, E.S., Bayar Muluk, N., Cingi, C., Correa, A.G. (eds) Hearing Loss in Congenital, Neonatal and Childhood Infections. Comprehensive ENT. Springer, Cham. https://doi.org/10.1007/978-3-031-38495-0_73

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-38495-0_73

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-38494-3

  • Online ISBN: 978-3-031-38495-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation